What is the recommended management for a 61-year-old male on rosuvastatin 10 mg daily with total cholesterol 195 mg/dL, LDL‑C 132 mg/dL, HDL‑C 45 mg/dL, a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 7.4 %, who is a non‑smoker and has no history of diabetes or hypertension?

Recommendation for Lipid Management

Increase rosuvastatin to 20 mg once daily to achieve at least a 30% LDL-C reduction, as this patient with a 7.4% 10-year ASCVD risk falls into the intermediate-risk category and warrants moderate-intensity statin therapy. 1

Risk Stratification and Treatment Rationale

This 61-year-old male has a calculated 10-year ASCVD risk of 7.4%, placing him in the intermediate-risk category (7.5–19.9%) according to the 2018 ACC/AHA guidelines. 1 His current LDL-C of 132 mg/dL on rosuvastatin 10 mg indicates suboptimal response to his current low-intensity regimen.

Current Treatment Gap

• Rosuvastatin 10 mg is achieving inadequate LDL-C reduction. The patient's LDL-C remains at 132 mg/dL, which represents less than a 30% reduction from his likely baseline (estimated >180 mg/dL). 1
• For intermediate-risk patients (7.5–19.9% 10-year ASCVD risk), guidelines recommend moderate-intensity statin therapy targeting ≥30% LDL-C reduction. 1, 2
• His HDL-C of 45 mg/dL is borderline low, which may represent a risk-enhancing factor that further supports intensification of therapy. 1

Specific Dosing Recommendation

Increase to rosuvastatin 20 mg once daily. 3 This dose change is supported by:

• Rosuvastatin 20 mg is classified as high-intensity statin therapy and typically achieves 50–63% LDL-C reduction. 4 Even if the patient achieves only moderate reduction (30–50%), this would bring his LDL-C to approximately 70–92 mg/dL, which is appropriate for his risk level.
• The FDA-approved dosage range for rosuvastatin is 5–40 mg once daily, and 20 mg is well within the therapeutic range. 3
• Rosuvastatin 20 mg has superior LDL-C lowering compared to atorvastatin 40 mg and enables more patients to achieve NCEP goals at lower doses. 4, 5

Risk-Enhancing Factors to Consider

Before finalizing the dose increase, conduct a clinician-patient risk discussion to assess for risk-enhancing factors that might influence treatment intensity: 1

• Family history of premature ASCVD (men <55 years, women <65 years)
• Metabolic syndrome (assess waist circumference, triglycerides, blood pressure, fasting glucose)
• Chronic kidney disease (check eGFR and urine albumin)
• Chronic inflammatory conditions (rheumatoid arthritis, psoriasis, HIV)
• Ethnicity (South Asian ancestry carries higher risk)
• Elevated triglycerides ≥175 mg/dL 1, 6

Role of Coronary Artery Calcium (CAC) Scoring

If uncertainty remains about treatment intensity after the risk discussion, obtain a CAC score: 1, 2

• CAC = 0: May consider continuing current dose with lifestyle optimization, though statin therapy is still reasonable given his intermediate risk
• CAC 1–99: Strongly favors dose increase to rosuvastatin 20 mg, especially at age 61
• CAC ≥100 or ≥75th percentile: Definitively indicates need for intensified therapy to rosuvastatin 20 mg or higher 1, 2

Monitoring and Follow-Up

Reassess lipid panel 4–12 weeks after dose adjustment: 1

• Target LDL-C reduction of ≥30% from baseline (goal approximately <92 mg/dL for intermediate risk)
• If LDL-C remains >100 mg/dL on rosuvastatin 20 mg and CAC score is elevated or multiple risk-enhancing factors are present, consider further intensification to rosuvastatin 40 mg 1
• Monitor for statin-associated muscle symptoms (unexplained muscle pain, tenderness, weakness) and hepatic function 3

Common Pitfalls to Avoid

• Do not continue subtherapeutic dosing. Rosuvastatin 10 mg is insufficient for intermediate-risk patients who require ≥30% LDL-C reduction. 1
• Do not delay treatment intensification. With a 7.4% 10-year ASCVD risk, this patient has a 1-in-13 chance of a cardiovascular event in the next decade without adequate therapy. 1
• Do not overlook risk-enhancing factors. His borderline-low HDL-C (45 mg/dL) may indicate metabolic syndrome or other conditions that warrant more aggressive therapy. 1, 6
• Ensure shared decision-making. Discuss the absolute risk reduction, potential side effects, and patient preferences before finalizing the treatment plan. 1

Lifestyle Optimization

Reinforce heart-healthy lifestyle modifications concurrently with medication adjustment: 1

• Mediterranean or DASH dietary pattern
• ≥150 minutes/week moderate-intensity aerobic exercise
• Weight management (BMI <25 kg/m²)
• Smoking cessation (if applicable—this patient is a non-smoker)
• Limit alcohol to ≤2 drinks/day for men 3